论文部分内容阅读
目的:探讨IMP3蛋白在骨肉瘤组织中的表达及其临床意义。方法:选取骨肉瘤患者68例,以骨软骨瘤患者术后石蜡切片20例作为对照,应用SP免疫组化方法检测IMP3蛋白的表达,以分析其在骨肉瘤、骨软骨瘤组织中阳性表达的差异性及与预后的关系。结果:骨肉瘤组织中IMP3阴性、弱、中、强的表达依次为4.41%(3/68)、22.06%(15/68)、22.74%(19/68)、45.59%(31/68),与骨软骨瘤组织相比,IMP3在骨肉瘤的表达存在显著上调(P<0.01)。骨肉瘤中IMP3表达与骨肉瘤患者术后3年存活率呈负相关(P<0.01)。结论:IMP3与骨肉瘤的发生、发展及预后有关,可作为新的骨肉瘤标记物,具有重要的临床意义。
Objective: To investigate the expression of IMP3 protein in osteosarcoma and its clinical significance. Methods: Sixty-eight patients with osteosarcoma were selected. Twenty paraffin sections of osteochondroma were used as controls. The expression of IMP3 protein was detected by SP immunohistochemistry to analyze the expression of IMP3 in osteosarcoma and osteochondroma The difference and its relationship with prognosis. RESULTS: The negative, weak, moderate and strong expressions of IMP3 in osteosarcoma tissues were 4.41% (3/68), 22.06% (15/68), 22.74% (19/68), 45.59% (31/68) Compared with osteochondroma, the expression of IMP3 in osteosarcoma was significantly increased (P <0.01). The expression of IMP3 in osteosarcoma was negatively correlated with the 3-year survival rate of osteosarcoma patients (P <0.01). Conclusion: IMP3 is associated with the occurrence, development and prognosis of osteosarcoma and may be used as a new marker of osteosarcoma. It has important clinical significance.